Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Litifilimab (BIIB059) (BDCA2 Antibody) in Cutaneous Lupus Erythematosus. The expected timing is based on the latest available company guidance and may change.
01/28/26:- FDA granted Breakthrough Therapy for CLE; AMETHYST Ph3 data readout in 2027. 03/19/26:- AMETHYST Part A 24-week Ph2 results presented at AAD Mar 28, 2026; Ph3 readout expected 2027. 03/28/26:- AMETHYST Part A Ph2 met primary endpoint Week 16; Ph3 ongoing, blinded; readout still 2027.
Verification
Confirm timing and program details against the company announcement or filing.